Role for Cathepsin F in Invariant Chain Processing and Major Histocompatibility Complex Class II Peptide Loading by Macrophages

By Guo-Ping Shi,* Rebecca A.R. Bryant,† Richard Riese,* Steven Verhelst,‡ Christoph Driessen,‡ Zhenqiang Li,§ Dieter Bromme,§ Hidde L. Ploegh,‡ and Harold A. Chapman*

From the *Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School and the †Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115; and the §Department of Human Genetics, Mount Sinai School of Medicine, New York, New York 10029

Abstract

The major histocompatibility complex (MHC) class II–associated invariant chain (Ii) regulates intracellular trafficking and peptide loading of MHC class II molecules. Such loading occurs after endosomal degradation of the invariant chain to a ~3-kD peptide termed CLIP (class II–associated invariant chain peptide). Cathepsins L and S have both been implicated in degradation of Ii to CLIP in thymus and peripheral lymphoid organs, respectively. However, macrophages from mice deficient in both cathepsins S and L can process Ii and load peptides onto MHC class II dimers normally. Both processes are blocked by a cysteine protease inhibitor, indicating the involvement of an additional Ii-processing enzyme(s). Comparison of cysteine proteases expressed by macrophages with those found in splenocytes and dendritic cells revealed two enzymes expressed exclusively in macrophages, cathepsins Z and F. Recombinant cathepsin Z did not generate CLIP from Ii–MHC class II complexes, whereas cathepsin F was as efficient as cathepsin S in CLIP generation. Inhibition of cathepsin F activity and MHC class II peptide loading by macrophages exhibited similar specificity and activity profiles. These experiments show that cathepsin F, in a subset of antigen presenting cells (APCs), can efficiently degrade Ii. Different APCs can thus use distinct proteases to mediate MHC class II maturation and peptide loading.

Key words: cysteine protease • antigen presentation • protease inhibitor • proteolysis • antigen presenting cell

Introduction

The MHC class II–associated invariant chain (Ii) is a type II transmembrane protein that binds to the peptide binding groove of newly synthesized MHC class II α/β heterodimers, thus preventing their premature association with endogenous polypeptides. Ii also regulates intracellular trafficking of MHC class II dimers. The Ii NH₂-terminal cytoplasmic domain contains an endosomal targeting signal that promotes Ii/MHC class II trafficking through the endosomal compartments of APCs (1-4). Within endosomal/lysosomal compartments, the Ii luminal domain undergoes stepwise proteolytic degradation to yield progressively smaller fragments. The smallest fragment that contains both the NH₂-terminal endosomal targeting sequence and a COOH-terminal extension through the MHC class II peptide-binding groove has been termed li10. The li10 fragment is converted subsequently to CLIP (class II–associated invariant chain peptide), a ~3-kD peptide that is ultimately exchanged for antigenic peptide in the final step of peptide loading (5-9). Once free from endosomal retention, peptide-loaded MHC class II dimers move to the cell surface. Thus, the timing and pattern of proteolysis of li dictate the route of maturation of MHC class II molecules and likely the antigenic peptides that are ultimately presented.

Degradation of li10 to CLIP is an important regulatory step in the maturation of MHC class II dimers. First, only two of the known acidic cathepsins (Cats) have been demonstrated to degrade li10 to CLIP, Cats S and L (10-12). Cat S is the major li-degrading enzyme of B cells and dendritic cells, thus preventing their premature association with endogenous polypeptides. Ii also regulates intracellular trafficking of MHC class II dimers. The Ii NH₂-terminal cytoplasmic domain contains an endosomal targeting signal that promotes Ii/MHC class II trafficking through the endosomal compartments of APCs (1-4). Within endosomal/lysosomal compartments, the Ii luminal domain undergoes stepwise proteolytic degradation to yield progressively smaller fragments. The smallest fragment that contains both the NH₂-terminal endosomal targeting sequence and a COOH-terminal extension through the MHC class II peptide-binding groove has been termed li10. The li10 fragment is converted subsequently to CLIP (class II–associated invariant chain peptide), a ~3-kD peptide that is ultimately exchanged for antigenic peptide in the final step of peptide loading (5-9). Once free from endosomal retention, peptide-loaded MHC class II dimers move to the cell surface. Thus, the timing and pattern of proteolysis of li dictate the route of maturation of MHC class II molecules and likely the antigenic peptides that are ultimately presented.

Degradation of li10 to CLIP is an important regulatory step in the maturation of MHC class II dimers. First, only two of the known acidic cathepsins (Cats) have been demonstrated to degrade li10 to CLIP, Cats S and L (10-12). Cat S is the major li-degrading enzyme of B cells and den-
Materials and Methods

Splenocytes from Cat S-deficient mice have defective MHC class II peptide loading, and Cat S−/− mice exhibit defective Th1-type antibody responses. However, IgE and pulmonary eosinophilic responses to antigen challenge in these mice are normal (11). This dichotomy raises the possibility that additional mechanisms exist to promote peptide loading and MHC class II antigen presentation in these mice. Here we explore this possibility by examining MHC class II maturation in mice deficient in both Cat S and L, currently the only known proteases capable of efficiently degrading Ii beyond lip10 in vivo. Because lung and peripheral macrophages of Cat S−/− mice show normal peptide loading, we searched for additional cysteine proteases expressed preferentially in macrophages. We describe the identification and degrading functions of two such enzymes, Cats Z and F.

Mice were genotyped as C57BL/6J (B6) or 129/SvEv (129) on day 12. On day 15, mice were killed for serum collection and bronchoalveolar lavage. Lavage fluid eosinophils were visualized by eosin and hematoxylin staining of cytospin preparations. Total IgE levels in serum were measured by ELISA as described previously (11). In some experiments, Cat S−/− mice were also injected intraperitoneally with LHVS (100 mg/kg body weight) every 48 h starting 2 d before the OVA immunization to the end of the protocol. Both lavage fluids and serum were again collected.

Preparation of Mouse Cat F Polyclonal Antibodies. Mouse Cat F cDNA was digested with EcoRI and fused in frame with maltose binding protein expression vector pMAL-c (New England Biolabs). The construct was transformed into DH5α, and fusion protein expression was induced with 0.3 mM isopropyl-β-d-thiogalactoside for 7 h to overnight. Fusion protein was then separated on 10% SDS-PAGE and purified as described previously (23). The purified fusion protein was used as antigen to immunize rabbits for generating polyclonal antisera (Charles River Labs).

Cloning and Expression of Mouse Cat Z. Three partial EST-tag sequences (AA116604, AA870150, and AI304158) were used to design both 5′-end sense primer and 3′-end antisense primer. The full-length cDNA was generated with reverse transcription PCR

Mice were injected intraperitoneally with 8 mg of OVA 5 d later, and nebulized with 0.5% OVA in PBS on day 12. OVA in PBS on day 12. OVA in PBS on day 12. OVA in PBS on day 12. OVA in PBS on day 12.
results

Cat S–deficient mice show defective IgE responses in the presence of LHVS. Cat S–deficient mice mount IgE responses and develop pulmonary eosinophilia normally after immunization and challenge with OVA (11). Cat S is not required for a normal Th2-like immune response. However, when Cat S and wild-type mice were injected with the cysteine protease inhibitor LHVS (100 mg/kg i.p.) intraperitoneally every 48 h, the IgE response (Fig. 1) and perivascular eosinophilic infiltration (not shown) in lungs of OVA-immunized mice was totally abrogated. These results are similar to those observed with C57BL/6 mice injected with LHVS during immunization with OVA (24) and raise the possibility that a cysteine protease other than Cat S is required for IgE responses and pulmonary inflammation in this model. This finding led us to explore MHC class II processing and peptide loading in mice deficient in the two known cysteine proteases implicated in CLIP generation, Cats S and L (11, 12, 14).

MHC class II molecules from macrophages of Cat S/L double knockout mice have similar IgE responses to OVA immunization. However, LHVS (100 mg/kg i.p.) completely blocks the IgE response in Cat S–deficient mice. Presence of LHVS.

Cat S–deficient mice show defective IgE responses in the presence of LHVS. Cat S–deficient mice mount IgE responses and develop pulmonary eosinophilia normally after immunization and challenge with OVA (11). Cat S is not required for a normal Th2-like immune response. However, when Cat S and wild-type mice were injected with the cysteine protease inhibitor LHVS (100 mg/kg i.p.) intraperitoneally every 48 h, the IgE response (Fig. 1) and perivascular eosinophilic infiltration (not shown) in lungs of OVA-immunized mice was totally abrogated. These results are similar to those observed with C57BL/6 mice injected with LHVS during immunization with OVA (24) and raise the possibility that a cysteine protease other than Cat S is required for IgE responses and pulmonary inflammation in this model. This finding led us to explore MHC class II processing and peptide loading in mice deficient in the two known cysteine proteases implicated in CLIP generation, Cats S and L (11, 12, 14).

MHC class II molecules from macrophages of Cat S/L double knockout mice have similar IgE responses to OVA immunization. However, LHVS (100 mg/kg i.p.) completely blocks the IgE response in Cat S–deficient mice.
Cells were pulsed and then chased for 5 h to allow processing, and MHC class II heterodimers were immunoprecipitated. Splenocytes from Cat S"⁻⁻" mice showed identical accumulation of lip10 and were equally defective in peptide loading (Fig. 2 A). This was expected, because mouse splenocytes express little or no Cat L. However, alveolar macrophages from Cat S"⁻⁻" mice degraded li and loaded peptide identically to macrophages from wild-type mice (Fig. 2 B), although a low amount of lip10 accumulation was sometimes found in Cat S"⁻⁻" mouse macrophages. When the amounts of peptide-MHC complexes among the various samples were normalized by densitometry to MHC class II α chain in the boiled samples, instead of total radioactive protein, there was again no difference in formation of α/β peptide complexes among the various types of mice (not shown). Like alveolar macrophages, peritoneal macrophages from Cat S"⁻⁻" mice were found to process li and present antigen normally (Fig. 2 C). Thus, macrophages either have a mechanism of exchanging larger fragments of li for peptide that is distinct from splenocytes, or these cells express additional li processing enzyme(s) capable of generating CLIP.

We examined the importance of li processing for peptide loading in macrophages by exposing Cat S"⁻⁻" peritoneal macrophages to either low or high doses of the Cat S inhibitor LHVS. Prior studies showed that LHVS is selective for Cat S at low concentrations (<10 nM), whereas at higher concentrations additional cysteine proteases are inhibited (16, 25). In the presence of LHVS (5 nM), Cat S"⁻⁻" macrophages process MHC class II-li as effectively as controls (Fig. 2 C), consistent with the observation that macrophages from Cat S-deficient mice have unimpaired li processing and peptide loading. Macrophages cultured in 1 μM LHVS showed delayed li processing (accumulation of lip10) and peptide loading reminiscent of that seen in splenocytes from Cat S"⁻⁻" or Cat S"⁻⁻" mice. Thus, an additional cysteine protease(s) in macrophages might substitute for Cat S in these cells.

Identification of Cysteine Proteases Expressed Preferentially in Macrophages. We next compared the set of cysteine proteases expressed by macrophages, B cells, and dendritic cells. EST databases were screened for murine cysteine protease cDNAs as a source of DNA probes. Sequences were obtained for murine Cats O, W, K, Z, and F in addition to the major Cats H, B, L, and S. PCRs of reverse-transcribed mRNA and Northern blot analyses were used to compare the expression of these enzymes in macrophages, B cells, and dendritic cells. Cat W and K mRNA was not seen in these cells, consistent with prior reports (26, 27). Low levels of Cat O were found in both B cells and macrophages. Because this enzyme was comparable in both cell types, Cat O was not further studied. Two enzymes, Cat Z and Cat F, were found to be expressed in macrophages but not splenocytes or dendritic cells by Northern blot analysis (Fig. 3 A). Comparison of mRNA levels of Cats Z and F with levels of Cat S in macrophages shows the relative level of Cat S to be considerably higher. Whereas Cat S mRNA is also evident in splenocytes and dendritic cells, longer exposure of the Northern blot shown in Fig. 3 A did not reveal a signal for either Cat F or Z mRNA in these cell types (not shown). Also unlike macrophages, PCR amplification of reverse-transcribed RNA failed to reveal Cats Z and F in splenocytes. Cats Z and F were therefore characterized in more detail.

Full length cDNAs encoding murine Cats Z and F were obtained as described in Materials and Methods. Comparison of the predicted amino acid sequences of human and murine Cats reveals extensive homologies (78% for Cat F and 79% for Cat Z). Cat Z has Cat B–like sequences with murine Cats reveals extensive homologies (78% for Cat F and 79% for Cat Z). Cat Z has Cat B–like sequences with

---

**Figure 2.** MHC class II from Cat S"⁻⁻" mice load peptide normally. (A) Mouse splenocytes from wild-type, Cat S"⁻⁺⁺", and Cat S"⁻⁻" mice were pulsed for 1 h and chased overnight. Macrophages were then lysed in NP-40 lysis buffer, followed by immunoprecipitation with N22. The precipitates were either boiled (B) or nonboiled (NB) before separation on 12% SDS-PAGE. (B) Mouse alveolar macrophages were metabolically labeled and immunoprecipitated with N22 and separated on 12% SDS-PAGE as splenocytes as in A. (C) Mouse peritoneal macrophages from Cat S"⁻⁻" were incubated in LHVS (0 or 5 nM or 1 μM) overnight, followed by 1 h of pulse and overnight chase. Cells were then lysed, immunoprecipitated with N22, and separated on 12% SDS-PAGE.
Figure 3. Isolation and expression of mouse Cats F and Z. (A) Northern blot analysis. Total RNA (20 μg each) from mouse splenocytes, peritoneal macrophages, and flt-3-stimulated dendritic cells were separated on 1.2% agarose gel, blotted onto a nylon filter, and probed with full length mouse Cat F, Z, and S cDNAs. RNA loading control is shown by rRNAs (top panel). Both Cats F and Z can be detected from macrophages but not splenocytes or dendritic cells. In contrast, Cat S transcripts can be detected in all three cell types. (B) Amino acid sequence of mouse Cat Z. The active site amino acids are indicated with asterisks (*), and the potential sites for glycosylation are double underlined. Arrowheads indicate the potential cleavage sites of signal peptide and pro region of Cat Z. (C) Amino acid sequence of mouse Cat F. Arrowheads indicate the signal peptide and pro region cleavage sites. Three active site amino acids (Cys, His, and Asn) are indicated by asterisks (*), and three potential glycosylation sites are double underlined. The underlined region is the potential cystatin-like domain (32).

Figure 4. Cat F, but not Cat Z, fits the LHVS-inhibitable protease profile of macrophages. Recombinant Cat F (5 nM) was labeled with 125I–JPM565 in the presence or absence of LHVS at the indicated concentrations for 1 h at 37°C in pH 4.2 assay buffer with 3 mM dithiothreitol (DTT) and then separated on 12% SDS-PAGE (left). Cat Z-transfected 293 cells were lysed in lysis buffer, pH 4.2, and 100 μg of protein was incubated with 125I–JPM565 in the presence of 3 mM DTT and inhibitors and separated on 12% SDS-PAGE (right).

Table: Inhibitor Profiles of Recombinant Cat F and Z

| Inhibitor | Cat F (nM) | Cat Z (nM) |
|-----------|------------|------------|
| LHVS      | 10,000     | 10,000     |
| E64       | 100        | 100        |

Inhibitor profiles of recombinant Cat F and Z. An enzyme substituting for Cat S in APC Ii processing should be sensitive to inhibition by high concentrations of LHVS. Therefore, we tested the sensitivity of Cats F and Z to increasing concentrations of LHVS. To conduct these studies, we used a probe based on the epoxide E-64, a classical specific inhibitor of cysteine (17, 22). This inhibitor, JPM565, was iodinated, and the sensitivity of human Cats F and Z to LHVS was determined by competition of active-site labeling by 125I–JPM565. Recombinant Cat F was sensitive to LHVS but less so than Cat S. Inhibition is evident at 10–20 nM and virtually complete at 50 nM, making the enzyme ~10–50-fold less sensitive to LHVS than Cat S (Fig. 4, left). In contrast to Cat F, mouse Cat Z expressed in 293 cells can be inhibited by 20 μM of E64 but not 1 μM LHVS (Fig. 4, right). This observation indicates Cat Z is an unlikely candidate to account for LHVS-sensitive II processing observed in Cat S/L–deficient macrophages (Fig. 2). These findings are therefore consistent with Cat F being a target enzyme for these inhibitors.

In additional experiments using recombinant human Cat F and inhibitors of the cystatin family, hydrolysis of the colorimetric substrate, Z-Leu-Arg-MCA, by Cat F was found to be markedly inhibited by cystatin C (K_i = 0.532 ± 0.1991 nM). The purified enzyme was much less sensitive to cystatin A (K_i = 6.645 ± 0.862 nM) and cystatin B (K_i = 9.156 ± 1.287 nM). These findings are in agreement with the overall sequence similarity between Cats S and F and imply an “open” substrate-binding cleft for Cat F, in line with its marked endopeptidolytic activity (19). In contrast, recent observations suggest that human Cat Z confers stricter carboxypeptidase activity than Cat B. No endopeptidase activity was found with this exopeptidase, and no inhibition by cystatin C was detected even up to a concentration of 4 μM of inhibitor (33). Because Cat F, and not Cat Z, displayed the correct inhibitory profile with LHVS, we focused on the expression of this enzyme in murine macrophages.

Expression of Cat F in murine macrophages. Polyclonal antibodies were raised against a fusion protein comprised of the maltose-binding protein and a fraction of the mouse Cat F coding sequence (from Glu221 to Asn462). These antibodies were used to explore expression of Cat F in
Figure 5. Cat F is expressed in macrophages and not splenocytes. (A) Equal amounts, normalized to protein content, of mouse peritoneal macrophages, splenocytes, and Cat F-transfected 293 cell lysates were labeled with 125I-JPM565, preboiled for 5 min, and immunoprecipitated with mouse Cat F antibodies. The precipitates were separated on 12% SDS-PAGE. Cat F is not detected in splenocytes, whereas macrophages showed the 30–31-kD active Cat F that was also present in Cat F-transfected 293 cells. (B) Splenocyte lysates containing 10-fold greater protein content than macrophages were directly immunoprecipitated with Cat F antibodies without preboiling. Cat F can only be detected in macrophages and not splenocytes. The sequential lysates were then boiled and further immunoprecipitated with Cat S antibodies to reveal Cat S expression in both types of cells. (C) Peritoneal macrophages from wild-type, Cat B-deficient macrophages were labeled and immunoprecipitated with 125I-JPM565 was added to equal amounts of cell lysates, normalized for protein concentration, from macrophages and splenocytes. The lysates were then immunoprecipitated with anti-Cat F antibodies, and the precipitates were analyzed by SDS-PAGE and autoradiography to reveal active enzyme. Active site-labeled Cat F, migrating as a ~31–33 kD protein, was recovered from lysates of macrophages or but not splenocytes (Fig. 5 A). Notably, when cell lysates were boiled for 5 min before immunoprecipitation, the Cat F antibodies cross-reacted with and immunoprecipitated Cat S, seen as the lower band in the macrophage lane of Fig. 5 A. This was confirmed by performing immunoprecipitations with the Cat F antibody in Cat S-deficient mice (Fig. 5 C) as well as Cat S-transfected 293 cell lysates (data not shown).

To further determine whether low levels of Cat F are expressed in splenocytes, 125I-JPM565-labeled Cat F was immunoprecipitated from both splenocyte and macrophage lysates under conditions in which the splenocyte lysate contained 10-fold greater protein content than the macrophage lysate. This experiment was conducted without preboiling of lysates, which clearly diminishes Cat S cross-reactivity. Again, no Cat F signal can be detected from splenocytes (Fig. 5 B). However, a sequential Cat S immunoprecipitation revealed Cat S expression in both splenocytes and macrophages (Fig. 5 B). This is consistent with the results of Northern blot analyses (Fig. 3).

As judged by 25I-JPM565 labeling, activity of Cat F was blocked by 1 μM LHVS but not by a low dose of LHVS (5 nM; Fig. 5 C). Because Cat F migrates with a molecular mass similar to that of Cat B, we tested the possibility that Cat F polyclonal antibodies cross-react with Cat B. Cat B-deficient macrophages were labeled and immunoprecipitated with Cat F antibodies. Active Cat F was again observed (Fig. 5 C). In addition, the antibody specificity was also confirmed using Cat F-transfected 293 cell lysates. No active cysteine proteases were revealed by this antibody in sham-transfected cells nor in cells transfected with empty vector (pcDNA-I; Invitrogen Corp.; Fig. 5 C). We conclude that the 31–33-kD active Cat F is expressed in macrophages and not B cells.

Cat F degraded lip10 and generated CLIP. Recombinant enzymes were used to test the ability of Cats Z or F to degrade li to CLIP. The amounts of active enzyme were determined by active site titration as described (10). Complexes of full length li and MHC class II dimers were obtained by immunoprecipitation of metabolically labeled splenocytes in the presence of Con B. Con B inhibits endosomal ATPase, which disrupts the normal pH of these compartments and results in a blockade of li processing. Immunoprecipitated complexes were resuspended at acidic pH (pH 4.2) and exposed to various amounts of recombinant Cats as indicated in Fig. 6 A. After 1 h at 37°C, the reactions were stopped in SDS sample buffer, and the reaction products were separated by SDS-PAGE and visualized by autoradiography. The ability of these cysteine proteases to degrade lip10 was quantified by densitometry and normalized to that seen with 5 nM recombinant Cat S (Fig. 6 B). As reported previously, compared with Cat S, Cat B had no activity as an li-degrading protease (10). Murine Cat Z, expressed in 293 cells, did not degrade lip10 at any concentration tested (Fig. 6 B). In contrast, human Cat F was found to be as or more active than Cat S in lip10 degradation and CLIP formation (Fig. 6). Lysates of 293 cells expressing murine Cat F also degraded lip10, resulting in CLIP formation (Fig. 6 B), whereas cells expressing murine Cat Z had no activity in this assay.
lysate was examined with 125I–JPM565 active site labeling. Densitometry and analyzed on a 10–20% Tricine gel. The Cat F and Z activity from cell Cat F–, S–, and B– or mouse Cat F– and Z–transfected 293 cell lysates tease active site titration; reference 10) of purified recombinant human noprecipitates were digested with 5 nM (as determined by cysteine pro-
products were separated on 10–20% Tricine gel (Novex). (B) N22 immu-
timate 1183 Shi et al.

Discussion

Proteolytic processing of II is a critical determinant of the timing and location of MHC class II peptide loading. Although a number of proteases have been implicated in progressive COOH-terminal cleavages of II to produce lip10, only a limited number of cysteine proteases, i.e., Cats S and L, appear capable of degrading lip10 to generate CLIP. We have identified an additional protease capable of cleaving lip10 to form CLIP: Cat F. Our data support the conclusion that Cat F is a relevant protease in APC lip10 processing. First, purified Cat F is at least as potent as Cat S in II processing and CLIP formation (Fig. 6). Second, macrophages deficient in Cats S and L process II and load peptides onto MHC class II heterodimers normally (Fig. 2). Nonetheless, lip10 processing and peptide loading in these cells remains sensitive to high concentrations of the cysteine protease inhibitor LHVS. Concentrations of LHVS that result in abrogation of MHC class II αβ-peptide SDS-stable complexes in macrophages (Fig. 2 B) also inhibit Cat F (Figs. 4 and 5 B), consistent with Cat F being the protease responsible for II processing in the absence of Cats S and L. Finally, macrophages express active Cat F. Nonetheless, we cannot exclude the possibility that as yet unknown additional cysteine proteases contribute to lip10 processing in macrophages. Our data are consistent with the notion that in macrophages, Cat F substitutes for and potentially complements the function of Cat S in lip10 processing. If so, manipulation of lip10 processing and MHC class II maturation by APCs in vivo may require an inhibitor that attacks Cats F, L, and S. From the viewpoint of II processing, these three enzymes appear to form a distinct subfamily of papain-type cysteine proteases.

Professional APCs are functionally heterogeneous but have been clarified on the basis of distinct surface markers and morphology into lymphoid- and myeloid-like dendritic cells, B cells, and macrophages. Recent evidence indicates that flt-3 ligand promotes development of lymphoid-type dendritic cells, whereas GM-CSF promotes development of predominantly myeloid-type dendritic cells (34). B cells are functionally distinct from dendritic cells in that they can use their surface Ig to capture and process low levels of extracellular antigens. Macrophages also present antigen efficiently in the context of inflammation (35–39). Although all types of APCs appear to express Cat S, only macrophages express Cat F, whereas this enzyme is not detected in B cells or flt-3-stimulated murine dendritic cells (Figs. 2 A and 5 A). The different pH profiles of Cats F and S allow the possibility that these enzymes may function in distinct antigen processing compartments. The pH optimum of Cat F favors its main site to be the lysosome (19), whereas Cat S activity is present throughout the endosomal/lysosomal pathways (13). The trafficking of endogenous Cat inhibitors such as cystatin C may also favor, at least under some conditions, one enzyme over the other in lip10 processing. The true functional importance of the finding of a second lip10 processing enzyme in APCs will require gene deletion and analysis of mice with selective loss of Cat F.

The use of cysteine protease inhibitors in vivo has recently emerged as a strategy to regulate immune responses and the life cycle of certain parasites (40, 41). For example, mice infected with Leishmania major showed a shift of CD4+ T cell differentiation from Th2 to Th1 when mice were treated with the Cat B inhibitor CA074 (42). IgE responses and pulmonary eosinophilia in mice immunized with OVA are blocked by high concentrations of LHVS (24). That this blockade cannot be explained by simple inhibition of Cat S is now clear given the fact that IgE responses in this OVA model are normal in Cat S–deficient mice (Fig. 1). Th2-type T cell responses are still impaired in LHVS-treated, Cat S–deficient mice. The identification of Cat F as an LHVS-inhibitable protease (Fig. 4) fully competent to process II-p10 and generate CLIP (Fig. 6) may explain the normal Th2-type immune responses in these mice. Stimulated lung macrophages could thus play a more prominent role in antigen presentation than is currently believed. Further experiments are required to establish whether other populations of APCs within lungs express Cat F or if indeed lung macrophages, at least in the setting of airway inflammation, become fully competent and important for antibody responses to antigens that access the immune system by this route.

This work was supported by National Institutes of Health grants HL60942 (to G.-P. Shi), HL48716 (to H.A. Chapman), and K08AI01555 (to R. Riese), grants from the American Lung Association (to R. Riese) and the Cancer Research Institute (to R.A.R. Bryant), and a grant from AXYS Pharmaceuticals.
References

1. Cresswell, P. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12:259–293.
2. Germain, R.N. 1994. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell. 76:287–299.
3. Wolf, P.R., and H.L. Ploegh. 1995. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu. Rev. Cell Dev. Biol. 11:267–306.
4. Watts, C. 1997. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 15:821–850.
5. Sloan, V.S., P. Cameron, G. Porter, M. Gammon, M. Amaya, E. Mellins, and D.M. Zaller. 1995. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature. 375:802–806.
6. Sherman, M.A., D.A. Weber, and P.E. Jenson. 1995. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. Immunity. 3:197–205.
7. Fung-Leung, W.P., C.D. Surh, M. Liljedahl, J. Pang, D. Leturcq, P.A. Peterson, S.R. W ebb, and L. Karlsson. 1996. Antigen presentation and T cell development in H-2/M deficient mice. Science. 271:1278–1281.
8. Miyazaki, T., P. Wolf, S. Tourne, C. W altzinger, A. Dierich, N. Barois, H. Ploegh, C. Benoist, and D. Mathis. 1996. Essential role for cathepsin S in MHC class II peptide-loading pathway. Cell. 84:531–541.
9. Ghosh, P., M. Amaya, E. Mellins, and D.C. Wiley. 1995. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR. Nature. 378:457–462.
10. Riese, R.J., P.R. Wolf, D. Bromme, L.R. N atkin, J.A. Villadangos, H.L. Ploegh, and H.A. Chapman. 1996. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity. 4:357–366.
11. Shi, G.-P., J.A. Villadangos, G. Dranoff, C. Small, L. Gu, K.J. Haley, R. Riese, H.L. Ploegh, and H.A. Chapman. 1999. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity. 10:197–206.
12. Nakagawa, T.Y., W.H. Brissette, P.D. Lira, R.J. Griffiths, N. Petrushova, J. Stock, J.D. M cN eish, S.E. Eastman, E.D. Howard, S.R. Clarke, et al. 1999. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 10:207–217.
13. Driessen, C., R.A.R. Bryant, A.M. Lennon-Dumenil, J.A. Villadangos, P.R. Wolf, G.-P. Shi, H.A. Chapman, and H.L. Ploegh. 1999. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J. Cell Biol. 147:775–790.
14. Nakagawa, T., W. Roth, P. Wong, A. Nelson, A. Farr, J. Deussing, J.A. Villadangos, H. Ploegh, C. Peters, and A.Y. Rudensky. 1998. Cathepsin L: critical role in II degradation and CD4 T cell selection in the thymus. Science. 280:450–453.
15. Pierre, P., and I. M ellman. 1998. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell. 93:1135–1145.
16. Palmer, J.T., D. Rasnick, J.L. Klaus, and D. Bromme. 1995. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem. 38:3193–3196.
17. Meara, J.P., and D.H. Rich. 1996. Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors. J. Med. Chem. 39:3357–3366.
18. Bromme, D., and M.E. M cGrath. 1996. High level expression and crystallization of recombinant human cathepsin S. Protein Sci. 5:789–791.
19. Wang, B., G.-P. Shi, P.M. Yao, Z. Li, H.A. Chapman, and D. Bromme. 1998. Human cathepsin F. Molecular cloning, functional expression, tissue localization, and enzymatic characterization. J. Biol. Chem. 273:32000–32008.
20. Metlay, J.P., M.D. Witmer-Pack, R. Agger, M.T. Crowley, D. Lawless, and R.M. Steinman. 1990. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J. Exp. Med. 171:1753–1771.
21. Guarnieri, J.J. 1977. Influence of acute exposure to cigarette smoke on the alveolar macrophage system. J. Lab. Clin. Med. 89:1215–1224.
22. Shi, G.-P., J.S. M unger, J.P. Meara, D.H. Rich, and H.A. Chapman. 1992. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastolytic cysteine protease. J. Biol. Chem. 267:7258–7262.
23. Shi, G.-P., A.C. Webb, K.E. Foster, J.H. Knoll, C.A. Lemere, J.S. M unger, and H.A. Chapman. 1994. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J. Biol. Chem. 269:11530–11536.
24. Riese, R.J., J.R. Mitchell, J.A. Villadangos, G.-P. Shi, J.T. Palmer, E.R. Karp, G.T. De Sanctis, H.L. Ploegh, and H.A. Chapman. 1999. Cathepsin S activity regulates antigen presentation and immunity. J. Clin. Invest. 101:2351–2363.
25. Villadangos, J.A., R.J. Riese, C. Peters, H.A. Chapman, and H.L. Ploegh. 1997. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J. Exp. Med. 186:549–560.
26. Linnevers, C., S.P. Smeekens, and D. Bromme. 1997. Human cathepsin W, a putative cysteine protease predominantly expressed in CDB+ T-lymphocytes. FEBS Lett. 405:253–259.
27. Shi, G.-P., H.A. Chapman, S.M. Bhardwaj, C. DelLuee, Y.V. Reddy, and S.J. Weiss. 1995. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit O C 2. FEBS Lett. 357:129–134.
28. Quarashi, O., D.K. Nagler, T. Fox, J. Sivaraman, M. Cygler, J.S. Mort, and A.C. Storer. 1999. The occluding loop in cathepsin B defines the pH dependence of inhibition by its propeptide. Biochemistry. 38:5017–5023.
29. Nagler, D.K., and R. Menard. 1998. Human cathepsin X: a novel cysteine protease of the papain family with a very short proregion and unique insertions. FEBS Lett. 434:135–139.
30. Santamaria, I., G. Velasco, A.M. Pendas, A. Fueyo, and C. Lopez-Otin. 1998. Cathepsin Z, a novel human cysteine protease with a short propeptide domain and a unique chromosomal location. J. Biol. Chem. 273:16816–16823.
31. Nagler, D.K., T. Sulea, and R. Menard. 1999. Full-length cDNA of human cathepsin F predicts the presence of a cystatin domain at the N-terminus of the cysteine proteasezymogen. Biochem. Biophys. Res. Commun. 257:313–318.
32. Santamaria, I., G. Velasco, A.M. Pendas, A. Paz, and C. López-Otin. 1999. Molecular cloning and structural and functional characterization of human cathepsin F, a new cysteine proteinase of the papain family with a long propeptide domain. J. Biol. Chem. 274:13800–13809.
33. Nagler, D.K., R. Zhang, W. Tam, T. Sulea, E.O. Purisima, and R. Menard. 1999. Human cathepsin X: a cysteine protease with unique carboxypeptidase activity. Biochemistry. 38:12648–12654.
34. Pulendran, B., J.L. Smith, G. Caspary, K. Brasel, D. Pettit, E. Maraskovsky, and C.R. Maliszewski. 1999. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. USA. 96:1036–1041.
35. Burastero, S.E., Z. Magnani, C. Confetti, L. Abbuzzese, S. Oddera, P. Balbo, G.A. Rossi, and E. Crimi. 1999. Increased expression of the CD80 accessory molecule by alveolar macrophages in asthmatic subjects and its functional involvement in allergen presentation to autologous TH2 lymphocytes. J. Allergy Clin. Immunol. 103:1136–1142.
36. Claassen, I.J., A.D. Osterhaus, M. Poelen, N. Van Rooijen, and E. Claassen. 1998. Antigen detection in vivo after immunization with different presentation forms of rabies virus antigen. II. Cellular, but not humoral, systemic immune responses against rabies virus immune-stimulating complexes are macrophage dependent. Immunology. 94:455–460.
37. Cua, D.J., and S.A. Stohlman. 1997. In vivo effects of T helper cell type 2 cytokines on macrophage antigen-presenting cell induction of T helper subsets J. Immunol. 159:5834–5840.
38. Ceddia, M.A., and J.A. Woods. 1999. Exercise suppresses macrophage antigen presentation. J. Appl. Physiol. 87:2253–2258.
39. Wijburg, O.L., G.P. van den Dobbelsteijn, J. Vadolas, A. Sanders, R.A. Strugnell, N. van Rooijen. 1998. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur. J. Immunol. 28:479–487.
40. McKerrow, J.H., J.C. Engel, and C.R. Caffrey. 1999. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem. 7:639–644.
41. Engel, J.C., P.S. Doyle, I. Hsieh, and J.H. McKerrow. 1998. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med. 188:725–734.
42. Maekawa, Y., K. Himeno, H. Ishikawa, H. Hisaeda, T. Sakai, T. Dainichi, T. Asao, R.A. Good, and N. Katunuma. 1998. Switch of CD4+ T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis J. Immunol. 161:2120–2127.